Table 1 Baseline patient characteristics
Characteristics | Number (%) |
|---|---|
Age | |
 Median | 61 |
 Range | 34–70 |
Gender | |
 Male | 206 (62%) |
 Female | 126 (38%) |
Smoking status | |
 Never smoker | 141 (42.5%) |
 Current or ex-smoker | 191 (57.5%) |
ECOG PS | |
 0–1 | 304 (91.6%) |
 2 | 28 (8.4%) |
Histological subtype | |
 Adenocarcinoma | 154 (46.4%) |
 Squamous | 161 (48.5%) |
 Other histology | 17 (5.1%) |
T stage | |
 T1 | 59 (17.8%) |
 T2 | 122 (36.7%) |
 T3 | 74 (22.3%) |
 T4 | 77 (23.2%) |
N stage | |
 N0 | 24 (7.2%) |
 N1 | 29 (8.7%) |
 N2 | 221 (66.6%) |
 N3 | 58 (17.5%) |
Clinical stage | |
 III A | 197 (59.3%) |
 III B | 135 (40.7%) |
Treatment modality | |
 Surgery + chemoradiation | 115 (34.6%) |
 Concurrent chemoradiation | 217 (65.4%) |
Chemotherapy cycles | |
 Median | 4 |
 Range | 2–8 |
Chemotherapy regimen utilized | |
 Cisplatin + etoposide | 36 (10.8%) |
 Cisplatin + docetaxel | 150 (45.2%) |
 Cisplatin + paclitaxel | 61 (18.4%) |
 Cisplatin + vinorebine | 47 (14.2%) |
 Cisplatin + others | 38 (11.4%) |